PDF(Pubmed)
Abstract：
Cerenkov luminescence (CL) is a blue-weighted emission of light produced by a vast array of clinically approved radioisotopes and LINAC accelerators. When β particles (emitted during the decay of radioisotopes) are present in a medium such as water or tissue, they are able to travel faster than the speed of light in that medium and in doing so polarize the molecules around them. Once the particle has left the local area, the polarized molecules relax and return to their baseline state releasing the additional energy as light (luminescence). This blue glow has commonly been used to determine the output of nuclear power plant cores and, in recent years, has found traction in the preclinical and clinical imaging field. This brief review will discuss the technology which has enabled the emergence of the biomedical Cerenkov imaging field, recent pre-clinical studies with potential clinical translation of Cerenkov luminescence imaging (CLI) and the current clinical implementations of the method. Finally, an outlook is given as to the direction in which the field is heading.
摘要：
切伦科夫发光（CL）是由大量临床批准的放射性同位素和LINAC加速器产生的蓝光加权发射。当β粒子（在放射性同位素衰变过程中发射）存在于诸如水或组织的介质中时，它们能够比光速更快地在介质中传播，并使它们周围的分子偏振。一旦粒子离开了局部区域,偏振分子弛豫并返回到它们的基线状态,释放额外的能量作为光(发光)。这种蓝色辉光通常用于确定核电站堆芯的输出，近年来,在临床前和临床成像领域发现了牵引力。这篇简短的评论将讨论使生物医学切伦科夫成像领域出现的技术，最近的临床前研究与切伦科夫发光成像（CLI）的潜在临床翻译和该方法的当前临床实施。最后,给出了字段前进方向的展望。
